Brazilian E-cigarette Public Consultation: over 13,000 Suggestions Received

Regulations by 2FIRSTS.ai
Feb.26.2024
Brazilian E-cigarette Public Consultation: over 13,000 Suggestions Received
Brazil's health regulatory agency, Anvisa, received over 13,000 suggestions during a public consultation on e-cigarettes, sparking debates on regulation.

Recently, according to South American media Estadao, the Brazilian National Health Surveillance Agency (Anvisa) has concluded the public consultation on e-cigarettes. Data shows that during the online discussion period, the agency received over 13,000 suggestions from various sources.

 

Brazil currently has laws that prohibit all manufacturing, sales, importation, and promotion activities related to Electronic Nicotine Delivery Systems (ENDS). However, a public consultation is aimed at gathering opinions from the general public, academics, businesses, and any other relevant parties. This public consultation has also attracted 92 suggestions from foreign countries, with the majority coming from Canada and the United States, both of which have established regulations on e-cigarette sales.

 

In addition, Anvisa's Director-General Antonio Barra Torres has convened internal personnel to begin revising current regulations on e-cigarettes. Meanwhile, the bill 5008/2022 proposed by Congresswoman Soraya Thronicke is sparking debate within Congress. The bill aims to introduce new prohibitions on e-cigarette products, including banning the production of e-cigarettes with candy or dessert-related flavors, as well as packaging that is appealing to children and adolescents.

 

According to the statistical organization Ipec's data for 2023, there are currently 6 million adult smokers who have tried e-cigarettes, with 2.2 million of them already regularly using these e-cigarette products. This reflects the social discussions sparked by the public consultation, and these suggestions from the public will have a significant impact on Brazil's e-cigarette regulations.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
FDA Says Flavored ENDS Must Show “Added Benefit” as Small Manufacturers Seek Clearer Switching Benchmarks
During the FDA PMTA roundtable session on “Studies of Adult Benefit,” officials said flavored ENDS must demonstrate “added benefit” over tobacco-flavored products under the APPH standard, including sustained complete switching evidence. Small manufacturers questioned switching benchmarks, study duration, and bridging expectations.
Feb.11
Product | Clear Tank, Airflow Control and Three-Dimension Flavor Labels: RELX Launches Disposable DIVA in South Korea
Product | Clear Tank, Airflow Control and Three-Dimension Flavor Labels: RELX Launches Disposable DIVA in South Korea
RELX has recently launched its disposable e-cigarette, the RELX DIVA, on online channels in South Korea, offering two nicotine strengths of 0.98% and 1.98%. Publicly available information shows the device features a 20 mL e-liquid capacity and is rated for around 30,000 puffs, alongside a 750 mAh rechargeable battery and two power modes—BOOST and ECO—at approximately 16W and 13W, respectively.
Feb.05 by 2FIRSTS.ai
PMI Faces Setback in India: Global Regulatory Fragmentation Complicates Its Smoke-Free Transition
PMI Faces Setback in India: Global Regulatory Fragmentation Complicates Its Smoke-Free Transition
India has reaffirmed its 2019 ban on e-cigarettes and heated tobacco devices, effectively blocking Philip Morris International (PMI) from launching IQOS in the country despite years of lobbying. Together with Taiwan, China’s conditional opening of heated tobacco products, and Japan’s planned 2026 excise tax hikes, these moves highlight increasingly divergent national regulatory pathways—an external uncertainty shaping PMI’s smoke-free growth trajectory.
Feb.12
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
Research Summary | NHANES Study: Smoking or E-Cigarette Use Linked to Higher Prevalence of Elevated Blood Pressure and Hypertension
A cross-sectional analysis based on the US NHANES 2021–2023 cycle, including 6,262 participants aged over 12, found that compared with people who neither smoke nor vape, those who smoke and/or use e-cigarettes had a higher prevalence of elevated blood pressure and hypertension. After full adjustment, smoking/vaping was associated with elevated blood pressure (aOR 1.34) and hypertension (aOR 1.46), and with a 1.05 mmHg higher diastolic blood pressure.
Feb.09 by 2FIRSTS.ai
Malaysia joint operation seized $19,000 worth of vape liquid in Likas
Malaysia joint operation seized $19,000 worth of vape liquid in Likas
More than 2,300 units of vape liquid worth over RM75,000 were seized during an integrated operation at premises in Likas near Kota Kinabalu. During Ops Taring Landai E-Cigarette Mega on Feb 10 night, the Marine Police, Sabah Health Department officials and district police detected a shop displaying 92 types of vape pods and, after further searches, found 2,353 units of vape liquid stored on the premises.
Feb.11 by 2FIRSTS.ai
UK vape retailer VPZ to expand manufacturing, open 40 stores in 2026
UK vape retailer VPZ to expand manufacturing, open 40 stores in 2026
UK specialist vape retailer VPZ has launched a multi-million-pound investment programme to boost domestic production capacity and tighten supply-chain controls. The plan includes adding a fifth production line, opening 40 new stores across the UK in 2026 and creating hundreds of jobs, while establishing a bonded warehouse at its Edinburgh headquarters as regulation tightens and a vaping tax is planned.
Feb.02 by 2FIRSTS.ai